-
Article
Open AccessMultiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
Mutations in the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K), encoded by the PIK3CA gene, cause dysregulation of the PI3K pathway in 35–40% of patients with HR+/HER2– breast cancer. Preclinica...
-
Article
Open AccessCCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
Triple negative breast cancer (TNBC) is aggressive with limited treatment options upon recurrence. Molecular discordance between primary and metastatic TNBC has been observed, but the degree of biological hete...
-
Article
Chip** away at the lung cancer genome
Kinase inhibitors are now standard treatment for patients with lung cancer whose tumors harbor specific mutant kinases. Four recent studies, including three in this issue (pages 375–384